News
First-line drug in the treatment of hormone-dependent metastatic breast cancer in postmenopause
8 FebruaryWe are pleased to inform you that we obtained the marketing authorizations for the antitumor hormonal agent Toremifen VIVA Pharm, tables in doses of 20 mg (РК-ЛС-5№023518) and 60 mg (РК-ЛС-5№023519).
Toremifen Viva Pharm is indicated for the treatment of hormone-dependent metastatic breast cancer in postmenopause as a first-line drug, as well as for the prevention and treatment of dishormonal breast hyperplasia.
